Health
Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates – MarketWatch
Johnson & Johnson
JNJ,
-1.69%
said Thursday that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The vaccine provided a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates, the company said. Based on the strength of the data, a Phase 1/2a first-i…
Continue Reading
-
Noosa News24 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Business21 hours agoThese ASX 200 shares could rise 50% to 60%
-
General21 hours agoAustralia’s Myanmar community mourns earthquake losses
-
General23 hours agoPort’s lease a ‘mistake’ as major parties flag takeover